Does Evolocumab, as a PCSK9 Inhibitor, Ameliorate the Lipid Profile in Familial Hypercholesterolemia Patients? A Meta-Analysis of Randomized Controlled Trials

• Главные авторы: Seyyed Majid Eslami (Автор), Shekoufeh Nikfar (Автор), Maryam Ghasemi (Автор), Mohammad Abdollahi (Автор)
• Формат: ‌
• Опубликовано: Frontiers Media S.A., 2017-04-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Proprotein convertase subtilisin-kexin type 9 (PCSK9) is a member of regulatory serine proteases which is mostly expressed in liver. In the physiological condition, LDL-C binds to LDL receptors (LDLRs) and via endocytosis, LDLRs are degraded. PCSK9 binds to the epidermal growth factor-like repeat A...